Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment

The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the “post-acute COVID-19 syndrome....

Full description

Saved in:

Bibliographic Details
Published in:	CNS drugs Vol. 36; no. 7; pp. 681 - 702
Main Authors:	Mazza, Mario Gennaro, Palladini, Mariagrazia, Poletti, Sara, Benedetti, Francesco
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01.07.2022 Springer Nature B.V
Subjects:	Cognition Cognitive ability Coronaviruses COVID-19 Drug therapy Epidemiology Long COVID Medical treatment Medicine Medicine & Public Health Mental depression Mental disorders Meta-analysis Neurology Neurosciences Patients Pharmacotherapy Psychiatry Psychopathology Psychopharmacology Quality of life Review Review Article Severe acute respiratory syndrome coronavirus 2 Viral infections
ISSN:	1172-7047, 1179-1934, 1179-1934
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the “post-acute COVID-19 syndrome.” Depressive psychopathology was reported in around 35% of patients at short, medium, and long-term follow-up after the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. Post-COVID-19 depressive symptoms are known to increase fatigue and affect neurocognitive functioning, sleep, quality of life, and global functioning in COVID-19 survivors. The psychopathological mechanisms underlying post-COVID-19 depressive symptoms are mainly related to the inflammation triggered by the peripheral immune-inflammatory response to the viral infection and to the persistent psychological burden during and after infection. The large number of SARS-CoV-2-infected patients and the high prevalence of post-COVID-19 depressive symptoms may significantly increase the pool of people suffering from depressive disorders. Therefore, it is essential to screen, diagnose, treat, and monitor COVID-19 survivors’ psychopathology to counteract the depression disease burden and related years of life lived with disability. This paper reviews the current literature in order to synthesize the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms.
AbstractList	The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the “post-acute COVID-19 syndrome.” Depressive psychopathology was reported in around 35% of patients at short, medium, and long-term follow-up after the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. Post-COVID-19 depressive symptoms are known to increase fatigue and affect neurocognitive functioning, sleep, quality of life, and global functioning in COVID-19 survivors. The psychopathological mechanisms underlying post-COVID-19 depressive symptoms are mainly related to the inflammation triggered by the peripheral immune-inflammatory response to the viral infection and to the persistent psychological burden during and after infection. The large number of SARS-CoV-2-infected patients and the high prevalence of post-COVID-19 depressive symptoms may significantly increase the pool of people suffering from depressive disorders. Therefore, it is essential to screen, diagnose, treat, and monitor COVID-19 survivors’ psychopathology to counteract the depression disease burden and related years of life lived with disability. This paper reviews the current literature in order to synthesize the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms. The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the "post-acute COVID-19 syndrome." Depressive psychopathology was reported in around 35% of patients at short, medium, and long-term follow-up after the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. Post-COVID-19 depressive symptoms are known to increase fatigue and affect neurocognitive functioning, sleep, quality of life, and global functioning in COVID-19 survivors. The psychopathological mechanisms underlying post-COVID-19 depressive symptoms are mainly related to the inflammation triggered by the peripheral immuneinflammatory response to the viral infection and to the persistent psychological burden during and after infection. The large number of SARS-CoV-2-infected patients and the high prevalence of post-COVID-19 depressive symptoms may significantly increase the pool of people suffering from depressive disorders. Therefore, it is essential to screen, diagnose, treat, and monitor COVID-19 survivors' psychopathology to counteract the depression disease burden and related years of life lived with disability. This paper reviews the current literature in order to synthesize the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms. The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the "post-acute COVID-19 syndrome." Depressive psychopathology was reported in around 35% of patients at short, medium, and long-term follow-up after the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. Post-COVID-19 depressive symptoms are known to increase fatigue and affect neurocognitive functioning, sleep, quality of life, and global functioning in COVID-19 survivors. The psychopathological mechanisms underlying post-COVID-19 depressive symptoms are mainly related to the inflammation triggered by the peripheral immune-inflammatory response to the viral infection and to the persistent psychological burden during and after infection. The large number of SARS-CoV-2-infected patients and the high prevalence of post-COVID-19 depressive symptoms may significantly increase the pool of people suffering from depressive disorders. Therefore, it is essential to screen, diagnose, treat, and monitor COVID-19 survivors' psychopathology to counteract the depression disease burden and related years of life lived with disability. This paper reviews the current literature in order to synthesize the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms.The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the "post-acute COVID-19 syndrome." Depressive psychopathology was reported in around 35% of patients at short, medium, and long-term follow-up after the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. Post-COVID-19 depressive symptoms are known to increase fatigue and affect neurocognitive functioning, sleep, quality of life, and global functioning in COVID-19 survivors. The psychopathological mechanisms underlying post-COVID-19 depressive symptoms are mainly related to the inflammation triggered by the peripheral immune-inflammatory response to the viral infection and to the persistent psychological burden during and after infection. The large number of SARS-CoV-2-infected patients and the high prevalence of post-COVID-19 depressive symptoms may significantly increase the pool of people suffering from depressive disorders. Therefore, it is essential to screen, diagnose, treat, and monitor COVID-19 survivors' psychopathology to counteract the depression disease burden and related years of life lived with disability. This paper reviews the current literature in order to synthesize the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms.
Author	Mazza, Mario Gennaro Palladini, Mariagrazia Benedetti, Francesco Poletti, Sara
Author_xml	– sequence: 1 givenname: Mario Gennaro orcidid: 0000-0001-6613-2477 surname: Mazza fullname: Mazza, Mario Gennaro email: mazza.mariogennaro@hsr.it organization: Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Vita-Salute San Raffaele University, PhD Program in Cognitive Neuroscience, Vita-Salute San Raffaele University – sequence: 2 givenname: Mariagrazia surname: Palladini fullname: Palladini, Mariagrazia organization: Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Vita-Salute San Raffaele University, PhD Program in Cognitive Neuroscience, Vita-Salute San Raffaele University – sequence: 3 givenname: Sara surname: Poletti fullname: Poletti, Sara organization: Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Vita-Salute San Raffaele University – sequence: 4 givenname: Francesco surname: Benedetti fullname: Benedetti, Francesco organization: Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Vita-Salute San Raffaele University
BookMark	eNpdkVFrFDEQx4NUbHv6BXxa8MUHo0km2WR9EORatVDogdXXMJub3m3Z3azJXuG-vbleRfQpw8wv_2T4nbOTMY7E2Gsp3ksh7IeshaqBC6W4EA1IDs_YmZS24bIBffJYK26FtqfsPOd7IYSGun7BTsFYZQ3oM-ZXMc98efPz6qLcqi5oSpRz90DV9_0wzXHIH6vLqVvT0MU-bvbvqhXO2zht9_lPA8d1tdpiGjAcOl3AvrpNhPNA4_ySPb_DPtOrp3PBfny5vF1-49c3X6-Wn6_5pLSZuYMAqGTQrm3pTmKjmgCy1MKgdmhaMrapjTWaLIY6uAMhwUhdE0LbwoJ9OuZOu3agdShPJ-z9lLoB095H7Py_k7Hb-k188I2SwglRAt4-BaT4a0d59kOXA_U9jhR32avaNgqcdKagb_5D7-MujWW9QjnrlNXFy4LBkcrlE-OG0l9KCn8Q6I8CfRHoHwV6gN8gAo8v
ContentType	Journal Article
Copyright	The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 Copyright Springer Nature B.V. Jul 2022 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Copyright_xml	– notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 – notice: Copyright Springer Nature B.V. Jul 2022 – notice: 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
DBID	3V. 4T- 7QP 7TK 7X7 7XB 88E 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M1P M2M PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM
DOI	10.1007/s40263-022-00931-3
DatabaseName	ProQuest Central (Corporate) Docstoc Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Psychology Database (ProQuest) ProQuest One Academic ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Docstoc ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Psychology MEDLINE - Academic
Database_xml	– sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
EISSN	1179-1934
EndPage	702
ExternalDocumentID	PMC9210800 10_1007_s40263_022_00931_3
GroupedDBID	--- -EM 0R~ 29B 2JY 36B 3V. 4.4 406 53G 5GY 6I2 6PF 7X7 88E 8FI 8FJ 8R4 8R5 95. AAAUJ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AASML AATNV AAWTL AAYQN AAYTO ABAKF ABDZT ABFTV ABIPD ABIVO ABJNI ABJOX ABKCH ABKMS ABKTR ABPLI ABTKH ABTMW ABUWG ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFS ACMLO ACPIV ACPRK ACZOJ ADBBV ADFZG ADHHG ADJJI ADQRH ADRFC ADURQ ADZCM ADZKW AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEYRQ AFBBN AFKRA AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHIZS AHMBA AHSBF AIAKS AIGIU AILAN ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF ASPBG AUKKA AVWKF AWSVR AXYYD AZFZN AZQEC A~4 BENPR BGNMA BPHCQ BVXVI BYPQX CAG CCPQU COF CS3 DCUDU DPUIP DU5 DWQXO EBLON EBS EJD EMOBN ESX F5P FEDTE FIGPU FLLZZ FNLPD FSGXE FYUFA GNUQQ H13 HG6 HMCUK HVGLF IAO IEA IHR IMOTQ INH INR IPY ITC IWAJR J-C JZLTJ LLZTM M1P M2M M4Y NQJWS NU0 O9- OAC OPC OVD P2P PQQKQ PROAC PSQYO PSYQQ Q2X ROL RSV RZALA SISQX SJYHP SNPRN SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U9L UG4 UKHRP UTJUX VDBLX VFIZW W48 YFH YQY ~JE 4T- 7QP 7TK 7XB 8FK ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AFOHR AHWEU AIXLP ATHPR AYFIA K9. PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-p245t-83c3a21c48bbef1a929c31bbe05a48a5be57965754e7ac6c8a929135146ea3bb3
IEDL.DBID	BENPR
ISICitedReferencesCount	132
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000814008600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1172-7047 1179-1934
IngestDate	Tue Nov 04 01:48:01 EST 2025 Fri Sep 05 08:33:06 EDT 2025 Fri Nov 07 23:23:04 EST 2025 Fri Feb 21 02:45:26 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Language	English
License	This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-p245t-83c3a21c48bbef1a929c31bbe05a48a5be57965754e7ac6c8a929135146ea3bb3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0001-6613-2477
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC9210800
PMID	35727534
PQID	2687827426
PQPubID	33311
PageCount	22
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_9210800 proquest_miscellaneous_2679238185 proquest_journals_2687827426 springer_journals_10_1007_s40263_022_00931_3
PublicationCentury	2000
PublicationDate	2022-07-01
PublicationDateYYYYMMDD	2022-07-01
PublicationDate_xml	– month: 07 year: 2022 text: 2022-07-01 day: 01
PublicationDecade	2020
PublicationPlace	Cham
PublicationPlace_xml	– name: Cham – name: Auckland
PublicationTitle	CNS drugs
PublicationTitleAbbrev	CNS Drugs
PublicationYear	2022
Publisher	Springer International Publishing Springer Nature B.V
Publisher_xml	– name: Springer International Publishing – name: Springer Nature B.V
References	PolettiSAggioVBrioschiSDallaspeziaSColomboCBenedettiFMultidimensional cognitive impairment in unipolar and bipolar depression and the moderator effect of adverse childhood experiencesPsychiatry Clin Neurosci201771530931710.1111/pcn.1249728004481 WalkerFRNilssonMJonesKAcute and chronic stress-induced disturbances of microglial plasticity, phenotype and functionCurr Drug Targ20131411126212761:CAS:528:DC%2BC3sXhsFOiu7vN10.2174/13894501113149990208 Yuan B, Li W, Liu H, Cai X, Song S, Zhao J, et al. Correlation between immune response and self-reported depression during convalescence from COVID-19. Brain Behav Immun. 2020;88:39–43. https://doi.org/10.1016/j.bbi.2020.05.062. Eyo UB, Wu LJ. Bidirectional microglia-neuron communication in the healthy brain. Neural Plast. 2013;2013:456857. https://doi.org/10.1155/2013/456857. FarnooshGAkbariqomiMBadriTBagheriMIzadiMSaeedi-BoroujeniAEfficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: a randomized, double-blind clinical trialArch Med Res202253179851:CAS:528:DC%2BB3MXhsV2lu7vF10.1016/j.arcmed.2021.06.00634229896 LuYHoCSLiuXChuaANWangWMcIntyreRSChronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depressionPLoS ONE201712101:CAS:528:DC%2BC1cXhtFejtr3F10.1371/journal.pone.0186700290493485648231 AndersonGReiterRJMelatonin: Roles in influenza, Covid-19, and other viral infectionsRev Med Virol20203031:CAS:528:DC%2BB3cXptlejt7w%3D10.1002/rmv.2109323148507235470 MatschkeJLutgehetmannMHagelCSperhakeJPSchroderASEdlerCNeuropathology of patients with COVID-19 in Germany: a post-mortem case seriesLancet Neurol202019119199291:CAS:528:DC%2BB3cXitVSrtL3F10.1016/S1474-4422(20)30308-2330317357535629 DantzerRO'ConnorJCFreundGGJohnsonRWKelleyKWFrom inflammation to sickness and depression: when the immune system subjugates the brainNat Rev Neurosci20089146561:CAS:528:DC%2BD2sXhsVGjsbfJ10.1038/nrn2297180737752919277 Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs. placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–300. https://doi.org/10.1001/jama.2020.22760. Stefano GB, Buttiker P, Weissenberger S, Martin A, Ptacek R, Kream RM. Editorial: the pathogenesis of long-term neuropsychiatric COVID-19 and the role of microglia, mitochondria, and persistent neuroinflammation: a hypothesis. Med Sci Monit. 2021;27:e933015; https://doi.org/10.12659/MSM.933015. Tchekalarova J, Atanasova D, Kortenska L, Atanasova M, Lazarov N. Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling. Neurobiol Dis. 2018;115:127–44. https://doi.org/10.1016/j.nbd.2018.04.005. GraceAADysregulation of the dopamine system in the pathophysiology of schizophrenia and depressionNat Rev Neurosci20161785245321:CAS:528:DC%2BC28XptV2ju7g%3D10.1038/nrn.2016.57272565565166560 Borroto-Escuela DO, Ambrogini P, Chruscicka B, Lindskog M, Crespo-Ramirez M, Hernandez-Mondragon JC, et al. The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: a historical perspective and future prospects. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22041927. ZubairASMcAlpineLSGardinTFarhadianSKuruvillaDESpudichSNeuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a reviewJAMA Neurol20207781018102710.1001/jamaneurol.2020.2065324693877484225 MaesMVandoolaegheERanjanRBosmansEBergmansRDesnyderRIncreased serum interleukin-1-receptor-antagonist concentrations in major depressionJ Affect Disord1995361–229361:STN:280:DyaK2s7kt1SisA%3D%3D10.1016/0165-0327(95)00049-68988262 PapaioannouAIBartziokasKTsikrikaSKarakontakiFKastanakisEBanyaWThe impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbationsEur Respir J201341481582310.1183/09031936.0001311222878874 HashimotoYSuzukiTHashimotoKMechanisms of action of fluvoxamine for COVID-19: a historical reviewMol Psychiatry202210.1038/s41380-021-01432-3354779728985059 CebanFLingSLuiLMWLeeYGillHTeopizKMFatigue and cognitive impairment in Post-COVID-19 syndrome: a systematic review and meta-analysisBrain Behav Immun202129101931351:CAS:528:DC%2BB38Xnt1Gjsw%3D%3D10.1016/j.bbi.2021.12.020 HuangCWangYLiXRenLZhaoJHuYClinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet2020395102234975061:CAS:528:DC%2BB3cXhs1Kqu7c%3D10.1016/S0140-6736(20)30183-5319862647159299 MolteniRMacchiFZecchilloCDell'agliMColomboECalabreseFModulation of the inflammatory response in rats chronically treated with the antidepressant agomelatineEur Neuropsychopharmacol20132311164516551:CAS:528:DC%2BC3sXmsFCnsLw%3D10.1016/j.euroneuro.2013.03.00823622958 Spuch C, Lopez-Garcia M, Rivera-Baltanas T, Rodrigues-Amorim D, Olivares JM. Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol. 2020;11:557629. https://doi.org/10.3389/fphar.2020.557629. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22. https://doi.org/10.1016/j.bbi.2020.03.031. FurlanRMelloniEFinardiAVaiBDi ToroSAggioVNatural killer cells protect white matter integrity in bipolar disorderBrain Behav Immun2019814104211:CAS:528:DC%2BC1MXhsVals7bM10.1016/j.bbi.2019.06.037 HuangCHuangLWangYLiXRenLGuX6-month consequences of COVID-19 in patients discharged from hospital: a cohort studyLancet2021397102702202321:CAS:528:DC%2BB3MXhslWmurY%3D10.1016/S0140-6736(20)32656-8334288677833295 De LorenzoRLoréNIFinardiAMandelliACirilloDMTresoldiCBlood neurofilament light chain and total tau levels at admission predict death in COVID-19 patientsJ Neurol2021268124436444210.1007/s00415-021-10595-6 TownsendLDyerAHJonesKDunneJMooneyAGaffneyFPersistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infectionPLoS ONE202015111:CAS:528:DC%2BB3cXitlGgurnN10.1371/journal.pone.0240784331662877652254 Perrin AJ, Pariante CM. Endocrine and immune effects of non-convulsive neurostimulation in depression: a systematic review. Brain Behav Immun. 2020;87:910–20; https://doi.org/10.1016/j.bbi.2020.02.016. Kahve AC, Kaya H, Okuyucu M, Goka E, Barun S, Hacimusalar Y. Do anxiety and depression levels affect the inflammation response in patients hospitalized for COVID-19. Psychiatry Investig. 2021;18(6):505–12. https://doi.org/10.30773/pi.2021.0029. BenedettiFMazzaMCavalliGCiceriFDagnaLRovere-QueriniPCan cytokine blocking prevent depression in COVID-19 survivors?J Neuroimmune Pharmacol20211611310.1007/s11481-020-09966-z33107012 WohlebESFranklinTIwataMDumanRSIntegrating neuroimmune systems in the neurobiology of depressionNat Rev Neurosci20161784975111:CAS:528:DC%2BC28XpsFCmtbg%3D10.1038/nrn.2016.6927277867 MullinsNPowerRAFisherHLHanscombeKBEuesdenJIniestaRPolygenic interactions with environmental adversity in the aetiology of major depressive disorderPsychol Med20164647597701:STN:280:DC%2BC28znvVynsw%3D%3D10.1017/S003329171500217226526099 Juruena MF, Eror F, Cleare AJ, Young AH. The role of early life stress in HPA axis and anxiety. Adv Exp Med Biol. 2020;1191:141–53. https://doi.org/10.1007/978-981-32-9705-0_9. De BerardisDFornaroMOrsoliniLIasevoliFTomasettiCde BartolomeisAEffect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practiceCNS Spectr201722434234710.1017/S109285291600057227702411 HalarisAInflammation and depression but where does the inflammation come from?Curr Opin Psychiatry201932542242810.1097/YCO.000000000000053131192815 Zhou F, Wang RR, Huang HP, Du CL, Wu CM, Qian XM, et al. A randomized trial in the investigation of anxiety and depression in patients with coronavirus disease 2019 (COVID-19). Ann Palliat Med. 2021;10(2):2167–74; https://doi.org/10.21037/apm-21-212. BonafeMOlivieriFCavalloneLGiovagnettiSMayegianiFCardelliMA gender–dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevityEur J Immunol2001318235723611:CAS:528:DC%2BD3MXmt1ens7o%3D10.1002/1521-4141(200108)31:8<2357::aid-immu2357>3.0.co;2-x11500818 Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4). https://doi.org/10.3390/v12040372. RaadsheerFCHoogendijkWJStamFCTildersFJSwaabDFIncreased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patientsNeuroendocrinology19946044364441:STN:280:DyaK2M7isVGisg%3D%3D10.1159/0001267787824085 DongFLiuHLDaiNYangMLiuJPA living systematic review of the psychological problems in people suffering from COVID-19J Affect Disord202112921721881:CAS:528:DC%2BB3MXhtlegtbfJ10.1016/j.jad.2021.05.060 Ahmed GK, Khedr EM, Hamad DA, Meshref TS, Hashem MM, Aly MM. Long term impact of Covid-19 infection on sleep and mental health: a cross-sectional study. Psychiatry Res. 2021;305:114243. https://doi.org/10.1016/j.psychres.2021.114243. PietruczukKLisowskaKAGrabowskiKLandowskiJWitkowskiJMProliferation and apoptosis of T lymphocytes in patients with bipolar disorderSci Rep20188133271:CAS:528:DC%2BC1cXhs1Clu77F10.1038/s41598-018-21769-0294638755820246 Poletti S, Palladini M, Mazza MG, De Lorenzo R, group C-BOCS, Furlan R, et al. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life. Eur Arch Psychiatry Clin Neurosci. 2021. https://doi.org/10.1007/s00406-021-01346-9. SarrisJHerbal medicines in the treatment of psychiatric disorders: 10-year updated reviewPhytother Res20183271147116210.1002/ptr.605529575228 Cruz-PereiraJSReaKNolanYMO'LearyOFDinanTGCryanJFDepression's unholy trinity: dysregulated stress, imm
References_xml	– reference: SpudichSNathANervous system consequences of COVID-19Science202237565782672691:CAS:528:DC%2BB38XitFCrsb0%3D10.1126/science.abm205235050660 – reference: VaiBSerrettiAPolettiSMasciaMLorenziCColomboCCortico-limbic functional connectivity mediates the effect of early life stress on suicidality in bipolar depressed 5-HTTLPR*s carriersJ Affect Disord2020152634204271:CAS:528:DC%2BB3cXjvFOrtQ%3D%3D10.1016/j.jad.2019.11.142 – reference: CavalliGDe LucaGCampochiaroCDella-TorreERipaMCanettiDInterleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyLancet Rheumatol.202026e325e33110.1016/S2665-9913(20)30127-2325014547252085 – reference: KornhuberJMuehlbacherMTrappSPechmannSFriedlAReichelMIdentification of novel functional inhibitors of acid sphingomyelinasePLoS ONE2011681:CAS:528:DC%2BC3MXht1Wrt7bL10.1371/journal.pone.0023852219093653166082 – reference: NalbandianASehgalKGuptaAMadhavanMVMcGroderCStevensJSPost-acute COVID-19 syndromeNat Med20212746016151:CAS:528:DC%2BB3MXntVOrsro%3D10.1038/s41591-021-01283-z337539378893149 – reference: DavydowDSHoughCLZivinKLangaKMKatonWJDepression and risk of hospitalization for pneumonia in a cohort study of older AmericansJ Psychosom Res201477652853410.1016/j.jpsychores.2014.08.002251391254259844 – reference: DalyJLSimonettiBKleinKChenKEWilliamsonMKAnton-PlagaroCNeuropilin-1 is a host factor for SARS-CoV-2 infectionScience202037065188618651:CAS:528:DC%2BB3cXitlCmt7bI10.1126/science.abd3072330822947612957 – reference: PassavantiMArgentieriABarbieriDMLouBWijayaratnaKForoutan MirhosseiniASThe psychological impact of COVID-19 and restrictive measures in the worldJ Affect Disord20211528336511:CAS:528:DC%2BB3MXjtVSmt7Y%3D10.1016/j.jad.2021.01.020 – reference: De LorenzoRLoréNIFinardiAMandelliACirilloDMTresoldiCBlood neurofilament light chain and total tau levels at admission predict death in COVID-19 patientsJ Neurol2021268124436444210.1007/s00415-021-10595-6 – reference: StanfordSCRecent developments in research of melatonin and its potential therapeutic applicationsBr J Pharmacol201817516318731891:CAS:528:DC%2BC1cXhtlOrtrrN10.1111/bph.14371309172406057894 – reference: MullinsNPowerRAFisherHLHanscombeKBEuesdenJIniestaRPolygenic interactions with environmental adversity in the aetiology of major depressive disorderPsychol Med20164647597701:STN:280:DC%2BC28znvVynsw%3D%3D10.1017/S003329171500217226526099 – reference: BonafeMOlivieriFCavalloneLGiovagnettiSMayegianiFCardelliMA gender–dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevityEur J Immunol2001318235723611:CAS:528:DC%2BD3MXmt1ens7o%3D10.1002/1521-4141(200108)31:8<2357::aid-immu2357>3.0.co;2-x11500818 – reference: NasserieTHittleMGoodmanSNAssessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic reviewJAMA Netw Open20214510.1001/jamanetworkopen.2021.11417340377318155823 – reference: Poletti S, Mazza MG, Calesella F, Vai B, Lorenzi C, Manfredi E, et al. Circulating inflammatory markers impact cognitive functions in bipolar depression. J Psychiatr Res. 2021;140:110–6. https://doi.org/10.1016/j.jpsychires.2021.05.071. – reference: KohlerCAFreitasTHStubbsBMaesMSolmiMVeroneseNPeripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysisMol Neurobiol2018555419542061:CAS:528:DC%2BC2sXpvFGhtLo%3D10.1007/s12035-017-0632-128612257 – reference: Singh S, Roy D, Sinha K, Parveen S, Sharma G, Joshi G. Impact of COVID-19 and lockdown on mental health of children and adolescents: a narrative review with recommendations. Psychiatry Res. 2020;293:113429. https://doi.org/10.1016/j.psychres.2020.113429. – reference: RaadsheerFCHoogendijkWJStamFCTildersFJSwaabDFIncreased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patientsNeuroendocrinology19946044364441:STN:280:DyaK2M7isVGisg%3D%3D10.1159/0001267787824085 – reference: HegazyHGAliEHElgolyAHInterplay between pro-inflammatory cytokines and brain oxidative stress biomarkers: evidence of parallels between butyl paraben intoxication and the valproic acid brain physiopathology in autism rat modelCytokine20157121731801:CAS:528:DC%2BC2cXhvV2mtr7K10.1016/j.cyto.2014.10.02725461396 – reference: WakeHMoorhouseAJJinnoSKohsakaSNabekuraJResting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminalsJ Neurosci20092913397439801:CAS:528:DC%2BD1MXktlakt74%3D10.1523/JNEUROSCI.4363-08.2009193395936665392 – reference: KaoLTLiuSPLinHCLeeHCTsaiMCChungSDPoor clinical outcomes among pneumonia patients with depressive disorderPLoS ONE20149121:CAS:528:DC%2BC2MXpt1OksQ%3D%3D10.1371/journal.pone.0116436255513894281227 – reference: HoertelNSanchez-RicoMCougouleCGulbinsEKornhuberJCarpinteiroARepurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanismsMol Psychiatry202110.1038/s41380-021-01254-3348370608622106 – reference: HalarisAInflammation and depression but where does the inflammation come from?Curr Opin Psychiatry201932542242810.1097/YCO.000000000000053131192815 – reference: ZhouYHouYShenJMehraRKallianpurACulverDAA network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19PLoS Biol202018111:CAS:528:DC%2BB3cXis1enu7fM10.1371/journal.pbio.3000970331568437728249 – reference: TownsendLDyerAHJonesKDunneJMooneyAGaffneyFPersistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infectionPLoS ONE202015111:CAS:528:DC%2BB3cXitlGgurnN10.1371/journal.pone.0240784331662877652254 – reference: Serrano GarciaAMontanchez MateoJFranch PatoCMGomez MartinezRGarcia VazquezPGonzalezRIInterleukin 6 and depression in patients affected by Covid-19Med Clin (Engl Ed).202115673323351:CAS:528:DC%2BB3MXjslWgurw%3D10.1016/j.medcle.2020.11.013336885837931695 – reference: AliTRahmanSUHaoQLiWLiuZAli ShahFMelatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulationJ Pineal Res20206921:CAS:528:DC%2BB3cXhsVSrtrnI10.1111/jpi.1266732375205 – reference: Tremblay ME, Madore C, Bordeleau M, Tian L, Verkhratsky A. Neuropathobiology of COVID-19: the role for glia. Front Cell Neurosci. 2020;14:592214. https://doi.org/10.3389/fncel.2020.592214. – reference: HomolakJKodvanjIWidely available lysosome targeting agents should be considered as potential therapy for COVID-19Int J Antimicrob Agents20205621:CAS:528:DC%2BB3cXht1SrtrnI10.1016/j.ijantimicag.2020.106044325226747275137 – reference: VaiBMazzaMGDelli ColliCFoiselleMAllenBBenedettiFMental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysisLancet Psychiatry20218979781210.1016/S2215-0366(21)00232-7342740338285121 – reference: Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32. https://doi.org/10.1016/j.cytogfr.2020.05.003. – reference: Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Sarnelli G. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? Brain Behav Immun. 2020;87:93–4; https://doi.org/10.1016/j.bbi.2020.04.060. – reference: ArbourNDayRNewcombeJTalbotPJNeuroinvasion by human respiratory coronavirusesJ Virol20007419891389211:CAS:528:DC%2BD3cXmslymsLc%3D10.1128/jvi.74.19.8913-8921.200010982334102086 – reference: Organization WH. WHO Coronavirus (COVID-19) Dashboard. 2022. p. https://covid19.who.int/. – reference: Cruz-PereiraJSReaKNolanYMO'LearyOFDinanTGCryanJFDepression's unholy trinity: dysregulated stress, immunity, and the microbiomeAnnu Rev Psychol2020471497810.1146/annurev-psych-122216-011613 – reference: WalkerFRNilssonMJonesKAcute and chronic stress-induced disturbances of microglial plasticity, phenotype and functionCurr Drug Targ20131411126212761:CAS:528:DC%2BC3sXhsFOiu7vN10.2174/13894501113149990208 – reference: MazzaMGLucchiSTringaliAGMRossettiABottiERClericiMNeutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: a meta-analysisProg Neuropsychopharmacol Biol Psychiatry201884Pt A22923610.1016/j.pnpbp.2018.03.01229535038 – reference: CardinaliDPSrinivasanVBrzezinskiABrownGMMelatonin and its analogs in insomnia and depressionJ Pineal Res20125243653751:CAS:528:DC%2BC38XntFyltb0%3D10.1111/j.1600-079X.2011.00962.x21951153 – reference: DongFLiuHLDaiNYangMLiuJPA living systematic review of the psychological problems in people suffering from COVID-19J Affect Disord202112921721881:CAS:528:DC%2BB3MXhtlegtbfJ10.1016/j.jad.2021.05.060 – reference: WuTJiaXShiHNiuJYinXXieJPrevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysisJ Affect Disord20211528191981:CAS:528:DC%2BB3cXisFKjtrnO10.1016/j.jad.2020.11.117 – reference: LiuYHoRCMakAInterleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regressionJ Affect Disord201213932302391:CAS:528:DC%2BC38XosFWmu7g%3D10.1016/j.jad.2011.08.00321872339 – reference: Del Matto L, Muscas M, Murru A, Verdolini N, Anmella G, Fico G, et al. Lithium and suicide prevention in mood disorders and in the general population: a systematic review. Neurosci Biobehav Rev. 2020;116:142–53; https://doi.org/10.1016/j.neubiorev.2020.06.017. – reference: HeXZhangDZhangLZhengXZhangGPanKNeurological and psychiatric presentations associated with COVID-19Eur Arch Psychiatry Clin Neurosci20222721415210.1007/s00406-021-01244-033710424 – reference: Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:652688. https://doi.org/10.3389/fphar.2021.652688. – reference: Spuch C, Lopez-Garcia M, Rivera-Baltanas T, Rodrigues-Amorim D, Olivares JM. Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol. 2020;11:557629. https://doi.org/10.3389/fphar.2020.557629. – reference: PeckhamHde GruijterNMRaineCRadziszewskaACiurtinCWedderburnLRMale sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admissionNat Commun202011163171:CAS:528:DC%2BB3cXisFelt7jI10.1038/s41467-020-19741-6332989447726563 – reference: FelgerJCLotrichFEInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implicationsNeuroscience2013292461992291:CAS:528:DC%2BC3sXpslKrsrw%3D10.1016/j.neuroscience.2013.04.060 – reference: Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2022;54:1–6. https://doi.org/10.1016/j.euroneuro.2021.09.009. – reference: LiYCBaiWZHashikawaTThe neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patientsJ Med Virol20209265525551:CAS:528:DC%2BB3cXntlelsr4%3D10.1002/jmv.2572832104915 – reference: MurruAManchiaMHajekTNielsenRERybakowskiJKSaniGLithium's antiviral effects: a potential drug for CoViD-19 disease?Int J Bipolar Disord.202081211:CAS:528:DC%2BB3cXpvF2rurg%3D10.1186/s40345-020-00191-4324359207239605 – reference: CarpinteiroAEdwardsMJHoffmannMKochsGGrippBWeigangSPharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cellsCell Rep Med.20201810.1016/j.xcrm.2020.100142331639807598530 – reference: HuangCWangYLiXRenLZhaoJHuYClinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet2020395102234975061:CAS:528:DC%2BB3cXhs1Kqu7c%3D10.1016/S0140-6736(20)30183-5319862647159299 – reference: ZubairASMcAlpineLSGardinTFarhadianSKuruvillaDESpudichSNeuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a reviewJAMA Neurol20207781018102710.1001/jamaneurol.2020.2065324693877484225 – reference: SoltaniSTabibzadehAZakeriAZakeriAMLatifiTShabaniMCOVID-19 associated central nervous system manifestations, mental and neurological symptoms: a systematic review and meta-analysisRev Neurosci20213233513611:CAS:528:DC%2BB3MXpt1Ckt7Y%3D10.1515/revneuro-2020-010833618441 – reference: YirmiyaRGoshenIImmune modulation of learning, memory, neural plasticity and neurogenesisBrain Behav Immun20112521812131:CAS:528:DC%2BC3MXhtVSru7w%3D10.1016/j.bbi.2010.10.01520970492 – reference: Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;17(12):CD008851. https://doi.org/10.1002/14651858.CD008851.pub2. – reference: Pashaei Y. Drug repurposing of selective serotonin reuptake inhibitors: could these drugs help fight COVID-19 and save lives? J Clin Neurosci. 2021;88:163–72. https://doi.org/10.1016/j.jocn.2021.03.010. – reference: SmithJADasARaySKBanikNLRole of pro-inflammatory cytokines released from microglia in neurodegenerative diseasesBrain Res Bull201287110201:CAS:528:DC%2BC3MXhs12gsr3P10.1016/j.brainresbull.2011.10.00422024597 – reference: MaesMYirmyiaRNorabergJBreneSHibbelnJPeriniGThe inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depressionMetab Brain Dis200924127531:CAS:528:DC%2BD1MXhvVOjsro%3D10.1007/s11011-008-9118-119085093 – reference: Juruena MF, Eror F, Cleare AJ, Young AH. The role of early life stress in HPA axis and anxiety. Adv Exp Med Biol. 2020;1191:141–53. https://doi.org/10.1007/978-981-32-9705-0_9. – reference: Huarcaya-Victoria J, Barreto J, Aire L, Podesta A, Caqui M, Guija-Igreda R, et al. Mental health in COVID-2019 survivors from a general hospital in peru: sociodemographic, clinical, and inflammatory variable associations. Int J Ment Health Addict. 2021. https://doi.org/10.1007/s11469-021-00659-z. – reference: Tchekalarova J, Atanasova D, Kortenska L, Atanasova M, Lazarov N. Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling. Neurobiol Dis. 2018;115:127–44. https://doi.org/10.1016/j.nbd.2018.04.005. – reference: Paniz-MondolfiABryceCGrimesZGordonREReidyJLednickyJCentral nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)J Med Virol20209276997021:CAS:528:DC%2BB3cXhtFWlu7vO10.1002/jmv.2591532314810 – reference: MarquezEJChungCHMarchesRRossiRJNehar-BelaidDErogluASexual-dimorphism in human immune system agingNat Commun20201117511:CAS:528:DC%2BB3cXntFOmt7Y%3D10.1038/s41467-020-14396-9320297367005316 – reference: SchliengerRGMeierCREffect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?Am J Cardiovasc Drugs2003331491621:CAS:528:DC%2BD3sXmtVGmtb4%3D10.2165/00129784-200303030-0000114727927 – reference: Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1–12. https://doi.org/10.1016/j.bbi.2016.03.010. – reference: BenedettiFZanardiRMazzaMGAntidepressant psychopharmacology: is inflammation a future target?Int Clin Psychopharmacol2022373798110.1097/YIC.000000000000040335357329 – reference: Bottemanne H, Gouraud C, Hulot JS, Blanchard A, Ranque B, Lahlou-Laforet K, et al. Do anxiety and depression predict persistent physical symptoms after a severe COVID-19 episode? A prospective study. Front Psychiatry. 2021;12:757685. https://doi.org/10.3389/fpsyt.2021.757685. – reference: Raony I, de Figueiredo CS, Pandolfo P, Giestal-de-Araujo E, Oliveira-Silva Bomfim P, Savino W. Psycho-neuroendocrine-immune interactions in COVID-19: potential impacts on mental health. Front Immunol. 2020;11:1170. https://doi.org/10.3389/fimmu.2020.01170. – reference: MatschkeJLutgehetmannMHagelCSperhakeJPSchroderASEdlerCNeuropathology of patients with COVID-19 in Germany: a post-mortem case seriesLancet Neurol202019119199291:CAS:528:DC%2BB3cXitVSrtL3F10.1016/S1474-4422(20)30308-2330317357535629 – reference: FurlanRMelloniEFinardiAVaiBDi ToroSAggioVNatural killer cells protect white matter integrity in bipolar disorderBrain Behav Immun2019814104211:CAS:528:DC%2BC1MXhsVals7bM10.1016/j.bbi.2019.06.037 – reference: Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs. placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–300. https://doi.org/10.1001/jama.2020.22760. – reference: TurrinNPRivestSUnraveling the molecular details involved in the intimate link between the immune and neuroendocrine systemsExp Biol Med (Maywood)20042291099610061:CAS:528:DC%2BD2cXpsF2ntrY%3D10.1177/153537020422901003 – reference: Arteaga-Henriquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium. Front Psychiatry. 2019;10:458. https://doi.org/10.3389/fpsyt.2019.00458. – reference: Iglesias-Gonzalez M, Boigues M, Sanagustin D, Giralt-Lopez M, Cuevas-Esteban J, Martinez-Caceres E, et al. Association of serum interleukin-6 and C-reactive protein with depressive and adjustment disorders in COVID-19 inpatients. Brain Behav Immun Health. 2022;19:100405. https://doi.org/10.1016/j.bbih.2021.100405. – reference: Yuan B, Li W, Liu H, Cai X, Song S, Zhao J, et al. Correlation between immune response and self-reported depression during convalescence from COVID-19. Brain Behav Immun. 2020;88:39–43. https://doi.org/10.1016/j.bbi.2020.05.062. – reference: LorkiewiczPWaszkiewiczNBiomarkers of post-COVID depressionJ Clin Med2021101841421:CAS:528:DC%2BB3MXitFygs7%2FP10.3390/jcm10184142 – reference: IdaTHaraMNakamuraYKozakiSTsunodaSIharaHCytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxideNeurosci Lett200843232322361:CAS:528:DC%2BD1cXitVaqtb0%3D10.1016/j.neulet.2007.12.04718255223 – reference: HuangCHuangLWangYLiXRenLGuX6-month consequences of COVID-19 in patients discharged from hospital: a cohort studyLancet2021397102702202321:CAS:528:DC%2BB3MXhslWmurY%3D10.1016/S0140-6736(20)32656-8334288677833295 – reference: Gouraud C, Bottemanne H, Lahlou-Laforet K, Blanchard A, Gunther S, Batti SE, et al. Association between psychological distress, cognitive complaints, and neuropsychological status after a severe COVID-19 episode: a cross-sectional study. Front Psychiatry. 2021;12:725861. https://doi.org/10.3389/fpsyt.2021.725861. – reference: Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:16–25. https://doi.org/10.1016/j.neubiorev.2018.03.023. – reference: FernandesBSSteinerJMolendijkMLDoddSNardinPGoncalvesCAC-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysisLancet Psychiatry20163121147115610.1016/S2215-0366(16)30370-427838212 – reference: CebanFLingSLuiLMWLeeYGillHTeopizKMFatigue and cognitive impairment in Post-COVID-19 syndrome: a systematic review and meta-analysisBrain Behav Immun202129101931351:CAS:528:DC%2BB38Xnt1Gjsw%3D%3D10.1016/j.bbi.2021.12.020 – reference: MazzaMPalladiniMPolettiSBenedettiFP0086 Clinical and psychopathological predictors of fatigue in COVID-19 survivors: a machine learning studyEur Neuropsychopharmacol202153S60S611:CAS:528:DC%2BB38XhtVygtb0%3D10.1016/j.euroneuro.2021.10.086 – reference: Estrada-Reyes R, Valdes-Tovar M, Arrieta-Baez D, Dorantes-Barron AM, Quero-Chavez D, Solis-Chagoyan H, et al. The timing of melatonin administration is crucial for its antidepressant-like effect in mice. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19082278. – reference: Khraisat B, Toubasi A, AlZoubi L, Al-Sayegh T, Mansour A. Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors. Int J Psychiatry Clin Pract. 2021. https://doi.org/10.1080/13651501.2021.1993924. – reference: Valdes-TovarMEstrada-ReyesRSolis-ChagoyanHArguetaJDorantes-BarronAMQuero-ChavezDCircadian modulation of neuroplasticity by melatonin: a target in the treatment of depressionBr J Pharmacol201817516320032081:CAS:528:DC%2BC1cXnslSrs7c%3D10.1111/bph.14197295121366057892 – reference: Stefano GB, Buttiker P, Weissenberger S, Martin A, Ptacek R, Kream RM. Editorial: the pathogenesis of long-term neuropsychiatric COVID-19 and the role of microglia, mitochondria, and persistent neuroinflammation: a hypothesis. Med Sci Monit. 2021;27:e933015; https://doi.org/10.12659/MSM.933015. – reference: Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun. 2020;88:17–27. https://doi.org/10.1016/j.bbi.2020.05.038. – reference: Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge JJ, McIntyre RS, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry. 2022. https://doi.org/10.1080/15622975.2021.2013041. – reference: HashimotoYSuzukiTHashimotoKMechanisms of action of fluvoxamine for COVID-19: a historical reviewMol Psychiatry202210.1038/s41380-021-01432-3354779728985059 – reference: CebanFNogoDCarvalhoIPLeeYNasriFXiongJAssociation between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysisJAMA Psychiat202178101079109110.1001/jamapsychiatry.2021.1818 – reference: ThimmulappaRKMudnakudu-NagarajuKKShivamalluCSubramaniamKJTRadhakrishnanABhojrajSAntiviral and immunomodulatory activity of curcumin: a case for prophylactic therapy for COVID-19Heliyon.20217210.1016/j.heliyon.2021.e06350336550867899028 – reference: Benedetti F, Aggio V, Pratesi ML, Greco G, Furlan R. Neuroinflammation in bipolar depression. Front Psychiatry. 2020;11:71. https://doi.org/10.3389/fpsyt.2020.00071. – reference: LiuDWangZLiuSWangFZhaoSHaoAAnti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cellsNeuropharmacology20116145925991:CAS:528:DC%2BC3MXosFarurg%3D10.1016/j.neuropharm.2011.04.03321575647 – reference: BschorTLithium in the treatment of major depressive disorderDrugs20147488558621:CAS:528:DC%2BC2cXotFyrsL4%3D10.1007/s40265-014-0220-x24825489 – reference: Perrin AJ, Pariante CM. Endocrine and immune effects of non-convulsive neurostimulation in depression: a systematic review. Brain Behav Immun. 2020;87:910–20; https://doi.org/10.1016/j.bbi.2020.02.016. – reference: Babicki M, Bogudzinska B, Kowalski K, Mastalerz-Migas A. Anxiety and depressive disorders and quality of life assessment of poles—a study covering two waves of the COVID-19 pandemic. Front Psychiatry. 2021;12:704248; https://doi.org/10.3389/fpsyt.2021.704248. – reference: Ahmed GK, Khedr EM, Hamad DA, Meshref TS, Hashem MM, Aly MM. Long term impact of Covid-19 infection on sleep and mental health: a cross-sectional study. Psychiatry Res. 2021;305:114243. https://doi.org/10.1016/j.psychres.2021.114243. – reference: DallaspeziaSSuzukiMBenedettiFChronobiological therapy for mood disordersCurr Psychiatry Rep201517129510.1007/s11920-015-0633-626478195 – reference: LuYHoCSLiuXChuaANWangWMcIntyreRSChronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depressionPLoS ONE201712101:CAS:528:DC%2BC1cXhtFejtr3F10.1371/journal.pone.0186700290493485648231 – reference: WangJWuXLaiWLongEZhangXLiWPrevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysisBMJ Open20177810.1136/bmjopen-2017-017173288389035640125 – reference: Benedetti F, Palladini M, D’Orsi G, Furlan R, Ciceri F, Rovere-Querini P, et al. Mood-congruent negative thinking styles and cognitive vulnerability in depressed COVID-19 survivors: a comparison with Major Depressive Disorder. J Affect Disord. 2022 (in press). – reference: BalciogluYHYesilkayaUHGokcayHKirliogluSSMay the central nervous system be fogged by the cytokine storm in COVID-19?: an appraisalJ Neuroimmune Pharmacol202015334334410.1007/s11481-020-09932-9325294627287281 – reference: Borroto-Escuela DO, Ambrogini P, Chruscicka B, Lindskog M, Crespo-Ramirez M, Hernandez-Mondragon JC, et al. The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: a historical perspective and future prospects. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22041927. – reference: BenedettiFMazzaMCavalliGCiceriFDagnaLRovere-QueriniPCan cytokine blocking prevent depression in COVID-19 survivors?J Neuroimmune Pharmacol20211611310.1007/s11481-020-09966-z33107012 – reference: NassarAAzabANEffects of lithium on inflammationACS Chem Neurosci2014564514581:CAS:528:DC%2BC2cXmvVWjsL4%3D10.1021/cn500038f248031814063502 – reference: DengJZhouFHouWSilverZWongCYChangOThe prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysisAnn N Y Acad Sci202114861901111:CAS:528:DC%2BB3MXltFKmtbk%3D10.1111/nyas.1450633009668 – reference: Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2):ofab050. https://doi.org/10.1093/ofid/ofab050. – reference: Wu C, Zhou Z, Ni L, Cao J, Tan M, Wu X, et al. Correlation between anxiety-depression symptoms and immune characteristics in inpatients with 2019 novel coronavirus in Wuhan, China. J Psychiatr Res. 2021;141:378–84; https://doi.org/10.1016/j.jpsychires.2021.07.027. – reference: Fei L, Santarelli G, D'Anna G, Moretti S, Mirossi G, Patti A, et al. Can SSRI/SNRI antidepressants decrease the 'cytokine storm' in the course of COVID-19 pneumonia? Panminerva Med. 2021. https://doi.org/10.23736/S0031-0808.21.04436-0. – reference: AlbertPRWhy is depression more prevalent in women?J Psychiatry Neurosci201540421922110.1503/jpn.150205261073484478054 – reference: OnaolapoAYOnaolapoOJGlutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous moleculeWorld J Psychiatry.202111729731510.5498/wjp.v11.i7.297343271238311508 – reference: Bourgognon JM, Cavanagh J. The role of cytokines in modulating learning and memory and brain plasticity. Brain Neurosci Adv. 2020;4:2398212820979802. https://doi.org/10.1177/2398212820979802. – reference: MalhiGSTaniousMDasPCoulstonCMBerkMPotential mechanisms of action of lithium in bipolar disorder. Current understandingCNS Drugs201327213515310.1007/s40263-013-0039-023371914 – reference: Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22. https://doi.org/10.1016/j.bbi.2020.03.031. – reference: Rajkumar RP. Ayurveda and COVID-19: where psychoneuroimmunology and the meaning response meet. Brain Behav Immun. 2020;87:8–9. https://doi.org/10.1016/j.bbi.2020.04.056. – reference: MazzaMGPalladiniMDe LorenzoRBraviBPolettiSFurlanROne-year mental health outcomes in a cohort of COVID-19 survivorsJ Psychiatr Res20212214511812410.1016/j.jpsychires.2021.11.031 – reference: EskelundALiYBudacDPMullerHKGulinelloMSanchezCDrugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behaviorJ Neurochem201714211181311:CAS:528:DC%2BC2sXnslOju7c%3D10.1111/jnc.1404328407315 – reference: Cheng Y, Desse S, Martinez A, Worthen RJ, Jope RS, Beurel E. TNFalpha disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain Behav Immun. 2018;69:556–67; https://doi.org/10.1016/j.bbi.2018.02.003. – reference: Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34–9. https://doi.org/10.1016/j.bbi.2020.04.027. – reference: StellwagenDMalenkaRCSynaptic scaling mediated by glial TNF-alphaNature20064407087105410591:CAS:528:DC%2BD28Xjs1agt7k%3D10.1038/nature0467116547515 – reference: Rodrigues PrestesTRRochaNPMirandaASTeixeiraALSimoesESACThe anti-inflammatory potential of ACE2/angiotensin-(1–7)/mas receptor axis: evidence from basic and clinical researchCurr Drug Targ20171811130113131:CAS:528:DC%2BC2sXhtlelsLnL10.2174/1389450117666160727142401 – reference: LindenauJNoackHAsayamaKWolfGEnhanced cellular glutathione peroxidase immunoreactivity in activated astrocytes and in microglia during excitotoxin induced neurodegenerationGlia19982422522561:STN:280:DyaK1czps12ksA%3D%3D10.1002/(SICI)1098-1136(199810)24:2<252::AID-GLIA10>3.0.CO;2-Z – reference: PolettiSAggioVBrioschiSBollettiniIFaliniAColomboCImpact of early and recent stress on white matter microstructure in major depressive disorderJ Affect Disord2018122528929710.1016/j.jad.2017.08.017 – reference: HanleyBNareshKNRoufosseCNicholsonAGWeirJCookeGSHistopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem studyLancet Microbe.202016e245e2531:CAS:528:DC%2BB3cXit1Kms7rN10.1016/S2666-5247(20)30115-4328441617440861 – reference: Mumtaz F, Khan MI, Zubair M, Dehpour AR. Neurobiology and consequences of social isolation stress in animal model—a comprehensive review. Biomed Pharmacother. 2018;105:1205–22; https://doi.org/10.1016/j.biopha.2018.05.086. – reference: PietruczukKLisowskaKAGrabowskiKLandowskiJWitkowskiJMProliferation and apoptosis of T lymphocytes in patients with bipolar disorderSci Rep20188133271:CAS:528:DC%2BC1cXhs1Clu77F10.1038/s41598-018-21769-0294638755820246 – reference: TaquetMGeddesJRHusainMLucianoSHarrisonPJ6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health recordsLancet Psychiatry20218541642710.1016/S2215-0366(21)00084-5338361488023694 – reference: ZunszainPAAnackerCCattaneoACarvalhoLAParianteCMGlucocorticoids, cytokines and brain abnormalities in depressionProg Neuropsychopharmacol Biol Psychiatry20113537227291:CAS:528:DC%2BC3MXkvVWgt7g%3D10.1016/j.pnpbp.2010.04.01120406665 – reference: TaquetMLucianoSGeddesJRHarrisonPJBidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USALancet Psychiatry20218213014010.1016/S2215-0366(20)30462-433181098 – reference: Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. J Neuroinflamm. 2013;10:43. https://doi.org/10.1186/1742-2094-10-43. – reference: WohlebESFranklinTIwataMDumanRSIntegrating neuroimmune systems in the neurobiology of depressionNat Rev Neurosci20161784975111:CAS:528:DC%2BC28XpsFCmtbg%3D10.1038/nrn.2016.6927277867 – reference: MorrisGBerkMKleinHWalderKGaleckiPMaesMNitrosative stress, hypernitrosylation, and autoimmune responses to nitrosylated proteins: new pathways in neuroprogressive disorders including depression and chronic fatigue syndromeMol Neurobiol2017546427142911:CAS:528:DC%2BC28XhtVCmtLjK10.1007/s12035-016-9975-227339878 – reference: Gomez L, Vidal B, Cabrera Y, Hernandez L, Rondon Y. Successful treatment of post-COVID symptoms with transcranial direct current stimulation. Prim Care Companion CNS Disord. 2021. https://doi.org/10.4088/PCC.21cr03059. – reference: YeQWangBMaoJThe pathogenesis and treatment of the `Cytokine Storm' in COVID-19J Infect20208066076131:CAS:528:DC%2BB3cXhtVantL%2FP10.1016/j.jinf.2020.03.037322831527194613 – reference: Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24–40. https://doi.org/10.1016/j.bbi.2019.06.015. – reference: ReisGDos Santos Moreira-SilvaEASilvaDCMThabaneLMilagresACFerreiraTSEffect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trialLancet Glob Health2022101e42e5110.1016/S2214-109X(21)00448-434717820 – reference: AndersonGMFluvoxamine, melatonin and COVID-19Psychopharmacology202123826111:CAS:528:DC%2BB3MXitV2gug%3D%3D10.1007/s00213-020-05753-z333926227779245 – reference: FarnooshGAkbariqomiMBadriTBagheriMIzadiMSaeedi-BoroujeniAEfficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: a randomized, double-blind clinical trialArch Med Res202253179851:CAS:528:DC%2BB3MXhsV2lu7vF10.1016/j.arcmed.2021.06.00634229896 – reference: BenedettiFBollettiniIBarberiIRadaelliDPolettiSLocatelliCLithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorderNeuropsychopharmacology20133823133271:CAS:528:DC%2BC38XhvVOrsLvP10.1038/npp.2012.172 – reference: LiXCaiQJiaZZhouYLiuLZhouYThe correlation between mental health status, sleep quality, and inflammatory markers, virus negative conversion time among patients confirmed with 2019-nCoV during the COVID-19 outbreak in China: an observational studyMedicine (Baltimore)2021100271:CAS:528:DC%2BB3MXhs1yjs7jL10.1097/MD.0000000000026520 – reference: Zhang R, Lam CLM, Peng X, Zhang D, Zhang C, Huang R, et al. Efficacy and acceptability of transcranial direct current stimulation for treating depression: a meta-analysis of randomized controlled trials. Neurosci Biobehav Rev. 2021;126:481–90. https://doi.org/10.1016/j.neubiorev.2021.03.026. – reference: Collaborators C-MD. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12. https://doi.org/10.1016/S0140-6736(21)02143-7. – reference: AndersonGReiterRJMelatonin: Roles in influenza, Covid-19, and other viral infectionsRev Med Virol20203031:CAS:528:DC%2BB3cXptlejt7w%3D10.1002/rmv.2109323148507235470 – reference: Liu C, Pan W, Li L, Li B, Ren Y, Ma X. Prevalence of depression, anxiety, and insomnia symptoms among patients with COVID-19: A meta-analysis of quality effects model. J Psychosom Res. 2021;147:110516; https://doi.org/10.1016/j.jpsychores.2021.110516. – reference: Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138–47; https://doi.org/10.1016/j.bbi.2021.02.021. – reference: Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. https://doi.org/10.1016/j.lfs.2020.117583. – reference: Hu Y, Chen Y, Zheng Y, You C, Tan J, Hu L, et al. Factors related to mental health of inpatients with COVID-19 in Wuhan, China. Brain Behav Immun. 2020;89:587–93. https://doi.org/10.1016/j.bbi.2020.07.016. – reference: Al-JassasHKAl-HakeimHKMaesMIntersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: a nomothetic network approachJ Affect Disord2022152972332451:CAS:528:DC%2BB3MXisVahsrzK10.1016/j.jad.2021.10.039 – reference: PapaioannouAIBartziokasKTsikrikaSKarakontakiFKastanakisEBanyaWThe impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbationsEur Respir J201341481582310.1183/09031936.0001311222878874 – reference: Cheng YC, Kuo PH, Su MI, Huang WL. The efficacy of non-invasive, non-convulsive electrical neuromodulation on depression, anxiety and sleep disturbance: a systematic review and meta-analysis. Psychol Med. 2022. https://doi.org/10.1017/S0033291721005560. – reference: MaesMVandoolaegheERanjanRBosmansEBergmansRDesnyderRIncreased serum interleukin-1-receptor-antagonist concentrations in major depressionJ Affect Disord1995361–229361:STN:280:DyaK2s7kt1SisA%3D%3D10.1016/0165-0327(95)00049-68988262 – reference: Kahve AC, Kaya H, Okuyucu M, Goka E, Barun S, Hacimusalar Y. Do anxiety and depression levels affect the inflammation response in patients hospitalized for COVID-19. Psychiatry Investig. 2021;18(6):505–12. https://doi.org/10.30773/pi.2021.0029. – reference: SimonMSSchiweckCArteaga-HenríquezGPolettiSHaarmanBCDikWAMonocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depressionProg Neuropsychopharmacol Biol Psychiatry20211111:CAS:528:DC%2BB3MXisFegtrzJ10.1016/j.pnpbp.2021.110391 – reference: Poletti S, Palladini M, Mazza MG, De Lorenzo R, group C-BOCS, Furlan R, et al. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life. Eur Arch Psychiatry Clin Neurosci. 2021. https://doi.org/10.1007/s00406-021-01346-9. – reference: DantzerRO'ConnorJCFreundGGJohnsonRWKelleyKWFrom inflammation to sickness and depression: when the immune system subjugates the brainNat Rev Neurosci20089146561:CAS:528:DC%2BD2sXhsVGjsbfJ10.1038/nrn2297180737752919277 – reference: FacenteSNReiersenAMLenzeEJBoulwareDRKlausnerJDFluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidenceDrugs20218118208120891:CAS:528:DC%2BB3MXis1GjsLrE10.1007/s40265-021-01636-5348515108633915 – reference: VenkatesanPNICE guideline on long COVIDLancet Respir Med2021921291:CAS:528:DC%2BB3MXhslWjuro%3D10.1016/S2213-2600(21)00031-X334531627832375 – reference: Cobley JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490–503. https://doi.org/10.1016/j.redox.2018.01.008. – reference: Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594–600; https://doi.org/10.1016/j.bbi.2020.07.037. – reference: Cava MA, Fay KE, Beanlands HJ, McCay EA, Wignall R. The experience of quarantine for individuals affected by SARS in Toronto. Public Health Nurs. 2005;22(5):398–406. https://doi.org/10.1111/j.0737-1209.2005.220504.x. – reference: MillerAHMaleticVRaisonCLInflammation and its discontents: the role of cytokines in the pathophysiology of major depressionBiol Psychiatry20096597327411:CAS:528:DC%2BD1MXktV2qsb0%3D10.1016/j.biopsych.2008.11.029191500532680424 – reference: Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–9. https://doi.org/10.1016/j.ejim.2020.05.021. – reference: Soni VK, Mehta A, Shukla D, Kumar S, Vishvakarma NK. Fight COVID-19 depression with immunity booster: Curcumin for psychoneuroimmunomodulation. Asian J Psychiatr. 2020;53:102378. https://doi.org/10.1016/j.ajp.2020.102378. – reference: Zhou F, Wang RR, Huang HP, Du CL, Wu CM, Qian XM, et al. A randomized trial in the investigation of anxiety and depression in patients with coronavirus disease 2019 (COVID-19). Ann Palliat Med. 2021;10(2):2167–74; https://doi.org/10.21037/apm-21-212. – reference: BlumeJDouglasSDEvansDLImmune suppression and immune activation in depressionBrain Behav Immun20112522212291:CAS:528:DC%2BC3MXhtVSru7o%3D10.1016/j.bbi.2010.10.00820955778 – reference: RogersJPChesneyEOliverDPollakTAMcGuirePFusar-PoliPPsychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemicLancet Psychiatry20207761162710.1016/S2215-0366(20)30203-0324376797234781 – reference: Benedetti F, Palladini M, Paolini M, Melloni E, Vai B, De Lorenzo R, et al. Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: A multimodal magnetic resonance imaging study. Brain Behav Immun Health. 2021;18:100387. https://doi.org/10.1016/j.bbih.2021.100387. – reference: BenedettiFPolettiSHoogenboezemTAMazzaEAmbréeOde WitHInflammatory cytokines influence measures of white matter integrity in bipolar disorderJ Affect Disord2016202191:CAS:528:DC%2BC28XptFOrsLo%3D10.1016/j.jad.2016.05.047 – reference: YadavBRaiAMundadaPSSinghalRRaoBCSRanaRSafety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: a structured summary of a study protocol for a randomized controlled trialTrials20212213781:CAS:528:DC%2BB3MXht1KhtbjJ10.1186/s13063-021-05326-1340827928173507 – reference: PaulERSchwielerLErhardtSBodaSTrepciAKampeRPeripheral and central kynurenine pathway abnormalities in major depressionBrain Behav Immun202261011361451:CAS:528:DC%2BB38XhtVOrtrjO10.1016/j.bbi.2022.01.002 – reference: NemeroffCBWiderlovEBissetteGWalleusHKarlssonIEklundKElevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patientsScience19842264680134213441:STN:280:DyaL2M%2FmsFOrtg%3D%3D10.1126/science.63343626334362 – reference: WalkerJBurkeKWanatMFisherRFieldingJMulickAThe prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studiesPsychol Med201848142285229810.1017/S003329171800062429576041 – reference: ParianteCMWhy are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammationEur Neuropsychopharmacol20172765545591:CAS:528:DC%2BC2sXmvVGqtbo%3D10.1016/j.euroneuro.2017.04.00128479211 – reference: Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4). https://doi.org/10.3390/v12040372. – reference: MattioliFStampatoriCRighettiFSalaETomasiCDe PalmaGNeurological and cognitive sequelae of Covid-19: a four month follow-upJ Neurol202126812442244281:CAS:528:DC%2BB3MXhtVaqsL7E10.1007/s00415-021-10579-6339321578088203 – reference: PolettiSAggioVBrioschiSDallaspeziaSColomboCBenedettiFMultidimensional cognitive impairment in unipolar and bipolar depression and the moderator effect of adverse childhood experiencesPsychiatry Clin Neurosci201771530931710.1111/pcn.1249728004481 – reference: GraceAADysregulation of the dopamine system in the pathophysiology of schizophrenia and depressionNat Rev Neurosci20161785245321:CAS:528:DC%2BC28XptV2ju7g%3D10.1038/nrn.2016.57272565565166560 – reference: HooperPLHeme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19Cell Stress Chaperones2022271341:CAS:528:DC%2BB3MXis1Gjs7nI10.1007/s12192-021-01246-w34846631 – reference: Xin M, Luo S, She R, Yu Y, Li L, Wang S, et al. Negative cognitive and psychological correlates of mandatory quarantine during the initial COVID-19 outbreak in China. Am Psychol. 2020;75(5):607–17. https://doi.org/10.1037/amp0000692. – reference: ThakurPShrivastavaRShrivastavaVKOxytocin as a potential adjuvant against COVID-19 infectionEndocr Metab Immune Disord Drug Targ2021217115511621:CAS:528:DC%2BB3MXhvFOjsbrJ10.2174/1871530320666200910114259 – reference: Eyo UB, Wu LJ. Bidirectional microglia-neuron communication in the healthy brain. Neural Plast. 2013;2013:456857. https://doi.org/10.1155/2013/456857. – reference: DantzerRNeuroimmune interactions: from the brain to the immune system and vice versaPhysiol Rev20189814775041:CAS:528:DC%2BC1MXisFektr0%3D10.1152/physrev.00039.201629351513 – reference: SarrisJHerbal medicines in the treatment of psychiatric disorders: 10-year updated reviewPhytother Res20183271147116210.1002/ptr.605529575228 – reference: Alnefeesi Y, Siegel A, Lui LMW, Teopiz KM, Ho RCM, Lee Y, et al. Impact of SARS-CoV-2 infection on cognitive function: a systematic review. Front Psychiatry. 2020;11:621773. https://doi.org/10.3389/fpsyt.2020.621773. – reference: Buemann B, Marazziti D, Uvnas-Moberg K. Can intravenous oxytocin infusion counteract hyperinflammation in COVID-19 infected patients? World J Biol Psychiatry. 2021;22(5):387–98; https://doi.org/10.1080/15622975.2020.1814408. – reference: De BerardisDFornaroMOrsoliniLIasevoliFTomasettiCde BartolomeisAEffect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practiceCNS Spectr201722434234710.1017/S109285291600057227702411 – reference: MaesMGaleckiPChangYSBerkMA review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illnessProg Neuropsychopharmacol Biol Psychiatry20113536766921:CAS:528:DC%2BC3MXkvVWgt70%3D10.1016/j.pnpbp.2010.05.00420471444 – reference: MolteniRMacchiFZecchilloCDell'agliMColomboECalabreseFModulation of the inflammatory response in rats chronically treated with the antidepressant agomelatineEur Neuropsychopharmacol20132311164516551:CAS:528:DC%2BC3sXmsFCnsLw%3D10.1016/j.euroneuro.2013.03.00823622958
SSID	ssj0004366
Score	2.6421146
SecondaryResourceType	review_article
Snippet	The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19...
SourceID	pubmedcentral proquest springer
SourceType	Open Access Repository Aggregation Database Publisher
StartPage	681
SubjectTerms	Cognition Cognitive ability Coronaviruses COVID-19 Drug therapy Epidemiology Long COVID Medical treatment Medicine Medicine & Public Health Mental depression Mental disorders Meta-analysis Neurology Neurosciences Patients Pharmacotherapy Psychiatry Psychopathology Psychopharmacology Quality of life Review Review Article Severe acute respiratory syndrome coronavirus 2 Viral infections
SummonAdditionalLinks	– databaseName: Springer Journals dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fS8MwED50ivjij6k4nRJBfFqgadI29U22iYLOoXP4VtI2wz2sHes22H9vkrWrE1_0rTRHWrhL77ve3XcA117EBtQKHexQXwcohOOQxRJzO_akcuexNH1r_Sev0-EfH343bwrLimr3IiVpvtSrZjcV6Zico411GE4w3YQt5e64Po6vb_2yG5KaDCVRrhl7FvPyVpnf91gDlj_LIn_kRo3Lud__38sewF4OMdHd0iYOYUMmVdh5zpPoVbjpLumqFw3UK7uvsga6Qd2SyHpxBIGe5IubL_3HFiY-auVFs3OJ3haj8TQdZbeoXU6YVft1FZ5Mzc-S_IZI4u-baotAvaK2_Rje79u95gPOBzLgsc2cKeY0osImEeNhKAdEKGgVUaKuLUcwLpxQ6s5WBQCZ9ETkRlxL6BGAzJWChiE9gUqSJvIUkB87grjKHqhUmIgyHtkytkI3ZpZUoILUoF7oJchPVRbYLleARgXzbg2uVsvqPOgkh0hkOtMymhFRw5AaeGv6DMZL_o5AM2qvryTDT8Os7du65NKqQaPQavnwFb-zUW2gVBsY1Qb07G_i57BrG8PQNb91qEwnM3kB29F8Oswml8aWvwAyBfE6 priority: 102 providerName: Springer Nature
Title	Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment
URI	https://link.springer.com/article/10.1007/s40263-022-00931-3 https://www.proquest.com/docview/2687827426 https://www.proquest.com/docview/2679238185 https://pubmed.ncbi.nlm.nih.gov/PMC9210800
Volume	36
WOSCitedRecordID	wos000814008600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1179-1934 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: 7X7 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1179-1934 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: BENPR dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1179-1934 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: M2M dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Journals customDbUrl: eissn: 1179-1934 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004366 issn: 1172-7047 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB6VpYde6FtdoMiVKk5rNX4kcXqpKCxqpbKNYLvaW-Q4RuVAspAFaW_9C_2L_SWMvV7S5dBLL3nZciz7s2fG8wJ4nxp5LqIyprHInIDCFC1lZaniVWqRnFfW-61NvqWjkZpOszwcuLXBrHK1J_qNumqMOyP_wBOFxAwFueTT7Iq6rFFOuxpSaGzApotUJnuw-Xk4yk87z0jhtZUMyTRNI5kGtxnvPIeSk9dhcurEekbFGpP50ETygZ7Uk5_jp__b8WewFRhPcrBEynN4ZOsXsJ8vI1cvBmTcOWK1A7JP8i6m9eIlGJfU98-v34ffJ1-P8M4ychRsaG8tOVtczubNZfuRDLuEs9hmjuxl489OwgddV3837ABCxitT91fw43g4PvxCQ34GOuMynlMljNCcGanK0p4zjZyWEQyfo1hLpePSOkdX5AelTbVJjHI1XEZAmVgtylK8hl7d1PYNkKyKNUsQHsIiiySkMtxWUZlUMrLIY7A-7K4GtwiLrC26ke3Du_tiXB5O56Fr29y4Oi5AouNK-pCuTWkxW4bzKFyA7fWS-uKnD7SdcWeBGfVhsJr87uf34Z49jAqEUeFhVIjtf_d1B55wDzpn8rsLvfn1jX0Lj83t_KK93oONdJr6q9oLYMa3E36C19OzyR0xbAEF
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VggQX_hFLCxgJelqLxHbiBAkh1G3VVZdlJZZqb2niuGoPTbbNttXeeAVepA_VJ2HGmzRsD9x64JQojpzI_jz-xvMH8F4bdSC9LOCBjElB8SOeqdzySOTa4naeWxe3tjfQw2E0mcSjFbhsYmHIrbKRiU5Q56WhM_KPIoxwM0NFLvwyPeFUNYqsq00JjQUsdu38AlW26nO_h_P7QYjtrfHmDq-rCvCpUMGMR9LIVPhGRVlmD_wU-YGRPt57QaqiNMgshWcii1FWpyY0Eb1BdexUaFOZZRL7vQN3UY5rciHTE93GYUpnG_WRFHDtKV0H6bhQPdTTnMVUcDpE8LlcorQ3HTJvWGXdZrf96H8bpsfwsKbV7OtiHTyBFVs8hY3RIi_3vMvGbZhZ1WUbbNRm7J4_A0Mli69-_d78vtfv4dWPWa_2ED637Mf8eDorj6tPbKstp4t9jpA8l-5kqH6QFvnfHRP82bhx5H8OP29lAF7AalEW9iWwOA9SP0TwS4sEUKrICJt7WZgrzyKD8juw3kxmUouQKmlnsgPvrptx8ZNFJy1seUbvUPpH4lwd0EsQSqaLZCUJpQ9fbimODl0a8ViQf6nXgW4Dtvbj18msHWwThG3iYJvIV__-17dwf2f8bZAM-sPdNXggHODJuXkdVmenZ_Y13DPns6Pq9I1bOgz2bxuEfwBYTFkP
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VghAX_hELBYwEPa3VxHYSBwkh1O2KVdslEkvVW0gcr9pDk22zLdobr8Dr8Dg8CTPepGF74NYDp0Rx5ET2N_Y3nj-AN5FRU-nlAQ9kTAqKr3muCsu1KCKL23lhXdzawV40HuvDwzhZg19tLAy5VbZroluoi8rQGfmWCDVuZqjIhVvTxi0iGQw_zE45VZAiS2tbTmMJkV27-I7qW_1-NMC5fivEcGey_Yk3FQb4TKhgzrU0MhO-UTrP7dTPkCsY6eO9F2RKZ0FuKVQTGY2yUWZCo-kNqmmnQpvJPJfY7w24GakgoOoJ-2K_i8mUzk7qI0HgkaeiJmDHhe2hzuasp4LTgYLP5Qq9veqcecVC6za-4b3_ecjuw92GbrOPS_l4AGu2fAibyTJf96LPJl34Wd1nmyzpMnkvHoGhUsa_f_zc_nwwGuDVj9mg8Ry-sOzL4mQ2r07qd2ynK7OLfSZIqit3YtQ8yMri745JLNikdfB_DF-vZQCewHpZlfYpsLgIMj9EoZAWiaFU2ghbeHlYKM8is_J7sNFObNosLXXazWoPXl8246JAlp6stNU5vUNpIYmL9SBagVM6WyYxSSmt-GpLeXzk0ovHgvxOvR70W-B1H79Mcu0gnCKEUwfhVD7797--gtuIvXRvNN59DneEwz75PG_A-vzs3L6AW-ZiflyfvXRSxODbdWPwD4lsYdI
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Post-COVID-19+Depressive+Symptoms%3A+Epidemiology%2C+Pathophysiology%2C+and+Pharmacological+Treatment&rft.jtitle=CNS+drugs&rft.au=Mazza%2C+Mario+Gennaro&rft.au=Palladini%2C+Mariagrazia&rft.au=Poletti%2C+Sara&rft.au=Benedetti%2C+Francesco&rft.date=2022-07-01&rft.issn=1179-1934&rft.eissn=1179-1934&rft.volume=36&rft.issue=7&rft.spage=681&rft_id=info:doi/10.1007%2Fs40263-022-00931-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1172-7047&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1172-7047&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1172-7047&client=summon